Clinical Trial Update: Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial entry (INSTAR) evaluating amivantamab in combination with lazertinib or with chemotherapy in EGFR-mutant locally advanced or metastatic/r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Lazertinib (lazertinib)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING